Fig. 4
Anti-melanoma efficacy in vivo. (A) Schematic illustration of establishment of tumor-bearing mice model and therapeutic regimens. (B) Ex vivo tumors at the end of the treatments. (1. Control, 2. CBD (i.p.), 3. CBD-SD@DMNs, 4. NaHCO3/CBD-SD@DMNs, and 5. Ef/CBD-SD@DMNs.) (C) Tumor growth curve of mice treated with various treatments. Data are represented as mean ± SD, n = 5. *P < 0.05. **P < 0.01. ***P < 0.001. (D) The ratio of tumor volume on day 15 to day 9. Data are represented as mean ± SD, n = 5. *P < 0.05. **P < 0.01. ***P < 0.001. (E) Tumor index and (F) body weight of tumor-bearing mice treated with different treatments. Data are represented as mean ± SD, n = 5. *P < 0.05. **P < 0.01. ***P < 0.001. (G) H&E-stained tumor sections after different treatments. The bar is 500 μm. (H) Immunofluorescence staining of TUNEL of tumor sections after different treatments. The bar is 1 mm. (I) Fluorescence images of tumor sections of mice treated with various C6-labeled formulations. The bar is 2 mm